Entrada Therapeutics Inc.
- Address
- 1 Design Center Place Suite 17-500
Sponsor Overview
Specializations
Duchenne Muscular Dystrophy
Entrada Therapeutics Inc. focuses its clinical research on Duchenne muscular dystrophy, with studies targeting patients whose disease is amenable to exon 44 skipping and exon 45 skipping.
- Neuromuscular disease
- Genetic muscle disorders
- Exon skipping therapies
The sponsor’s active trial portfolio includes recruiting studies across multiple countries and research sites, reflecting a concentrated interest in treatment areas relevant to DMD and its molecular subtypes.
Muscle Function and Disease Progression
Its clinical research activity is centered on preserving skeletal muscle function and addressing the progressive weakness associated with Duchenne muscular dystrophy.
- Muscle degeneration
- Motor impairment
- Progressive neuromuscular decline
These studies align with therapeutic interests in the clinical management of muscle loss, mobility limitation, and disease-related functional deterioration.
Genotype-Directed Therapeutics
The sponsor’s programs are directed toward mutation-specific approaches in Duchenne muscular dystrophy, particularly patients eligible for exon 44 or exon 45 skipping.
- RNA-targeted therapy
- Mutation-specific treatment
- Precision medicine
This area of interest reflects a focus on therapies tailored to defined genetic subgroups within the broader muscular dystrophy population.
Clinical Safety and Tolerability
Across its current studies, Entrada Therapeutics Inc. is evaluating the safety and tolerability of investigational therapies in participants with Duchenne muscular dystrophy.
- Treatment safety
- Therapeutic tolerability
- Patient monitoring
Its research activity is concentrated in neuromuscular medicine, with ongoing attention to clinical outcomes relevant to long-term treatment use.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of ENTR-601-44 in Duchenne Muscular Dystrophy Patients Amenable to Exon 44 Skipping: A Randomized, Double-Blind, Placebo-Controlled Study |  Belgium Italy Spain | Recruiting |
| Phase 2 Open‑Label Extension of ENTR‑601‑45 (with ENTR‑601‑44) in Exon‑Skipping‑Amenable Duchenne Muscular Dystrophy: Safety, Tolerability, PK and Efficacy | Belgium Italy Spain The Netherlands | Recruiting |
| Randomized, Double-Blind, Placebo-Controlled Study of ENTR-601-45 in Duchenne Muscular Dystrophy Patients Amenable to Exon 45 Skipping | Belgium Italy Spain The Netherlands | Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 0 are not being studied by other sponsors.
This sponsor has worked with 11 sites across their trial portfolio.
Therapeutic Focus
- 1.Musculoskeletal Diseases3 trials238 other sponsors
Partnered Research Centres
11 centres- Address
- Boulevard Du Douzieme De Ligne 1, 4000 Liège
- Address
- Piazza Dell'ospedale Maggiore 3, 20162 Milan
- Address
- Largo Francesco Vito 1, 00168 Rome
- Address
- Passeig De Sant Joan De Deu 2, 08950 Esplugues de Llobregat
- Address
- Passeig De La Vall D'Hebron 119-129, 08035 Barcelona
- Address
- Herestraat 49, 3000 Leuven
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Entrada Therapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.